AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
Saks Global Files for Bankruptcy Protection Amid Mounting Luxury Retail Pressures 
Netflix Plans All-Cash Bid for Warner Bros Discovery Studios Amid Intense Hollywood Takeover Battle 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
Trump Administration Approves Nvidia H200 AI Chip Sales to China Under New Export Rules 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Tesla, EEOC Move Toward Mediation in Racial Harassment Lawsuit 
Alphabet Stock Poised for Growth as Bank of America Sees Strong AI Momentum Into 2026 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
BlueScope Steel Announces A$1 Special Dividend After Asset Sales 
AFT Leaves X Over AI-Generated Images of Minors 
LOS ANGELES, March 31, 2017 -- Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against Regulus Therapeutics Inc. (“Regulus” or the “Company”) (Nasdaq:RGLS) concerning possible violations of federal securities laws between January 21, 2016 and June 27, 2016 inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the April 3, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, throughout the Class Period, Regulus made materially false and/or misleading statements, as well as failed to disclose material adverse facts about its business, operations, and prospects. On June 27, 2016, the Company announced that it received notice from the U.S. Food and Drug Administration (“FDA”) that its new drug for the treatment of chronic hepatitis C virus infection which was under FDA review, is now being put on clinical hold after a second serious case of jaundice was reported. When this information was released, the stock price of Regulus fell, causing investors harm.
Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and ethical rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
